Filters
In the treatment of patients with atopic dermatitis, the investigational tyrosine kinase 2 inhibitor ICP-332 demonstrates a favourable safety profile with promising efficacy, according to a phase II study.
In the treatment of patients with juvenile localized scleroderma, mycophenolate mofetil compares favourably with methotrexate in terms of reducing clinical activity and flare rate, according to a retrospective study.
Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.
In patients with prurigo nodularis, treatment with dupilumab provides consistent, meaningful improvements in pruritus while having a favourable safety profile, according to a meta-analysis.
The efficacy of unorthodox dosing regimens of tofacitinib and baricitinib is comparable among paediatric patients with moderate-to-severe alopecia areata over 24 weeks and has a manageable safety profile, reports a recent study.
Supplementation with niacinamide appears protective against some cardiovascular events, such as myocardial infarction and cardiac arrest, suggests a study.
New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Post-bacterial aetiology and the use of systemic corticosteroid appear protective against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), reveals a study.
A 15-year study recommends taking into consideration the differential risks of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivations when choosing targeted therapies for the treatment of psoriasis and psoriatic arthritis (PsA), particularly in patients with risk factors for viral reactivation.
Treatment with biologics results in short-term improvements of joint synovitis and enthesitis in patients with subclinical psoriatic arthritis (PsA), specifically for small joint synovitis, a study has shown.
